1. Home
  2. XNET vs LXEO Comparison

XNET vs LXEO Comparison

Compare XNET & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xunlei Limited

XNET

Xunlei Limited

HOLD

Current Price

$4.93

Market Cap

358.4M

Sector

Technology

ML Signal

HOLD

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$4.76

Market Cap

396.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
XNET
LXEO
Founded
2003
2017
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
358.4M
396.5M
IPO Year
2011
2023

Fundamental Metrics

Financial Performance
Metric
XNET
LXEO
Price
$4.93
$4.76
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$18.44
AVG Volume (30 Days)
219.1K
910.0K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.81
EPS
N/A
N/A
Revenue
N/A
$654,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.52
$3.99
52 Week High
$11.03
$10.99

Technical Indicators

Market Signals
Indicator
XNET
LXEO
Relative Strength Index (RSI) 42.00 47.67
Support Level $4.78 $4.39
Resistance Level $6.09 $5.38
Average True Range (ATR) 0.19 0.27
MACD 0.01 -0.02
Stochastic Oscillator 35.71 15.29

Price Performance

Historical Comparison
XNET
LXEO

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: